Purple Biotech Ltd. (PPBT) 10-Year Financial Performance & Capital Metrics

PPBT • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutPurple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.Show more

Revenue $0 -100.0%
EBITDA -$11M +51.3%
Net Income -$7M -36318.5%
EPS (Diluted) -4.42 -2662.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -21.55% -44049.8%
ROIC -36% +43.2%
Debt/Equity 0.01 -45.7%
Interest Coverage -24.62 -141.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓High quality earnings: Operating CF exceeds net income
✓Trading at only 0.1x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 9 (bottom 9%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM72.06%

EPS CAGR

10Y-

5Y-

3Y-

TTM-36734.22%

ROCE

10Y Avg-55.4%

5Y Avg-35.41%

3Y Avg-41.26%

Latest-31.37%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	100K	1M	1M	1M	0	0	195.8K	0
Revenue Growth %	-	-	-	9%	0%	0%	-1%	-	-	-1%
Cost of Goods Sold+	0	0	0	0	80	58	55	120	196K	186K
COGS % of Revenue	-	-	-	-	0%	0%	-	-	1%	-
Gross Profit+	0	0	100K	1M	999.92K	999.94K	-55	-120	-196	-186K
Gross Margin %	-	-	1%	1%	1%	1%	-	-	-0%	-
Gross Profit Growth %	-	-	-	9%	-0%	0%	-1%	-1.18%	-0.63%	-947.98%
Operating Expenses+	4.07M	7.18M	12.06M	8.83M	8.75M	13.24M	17.93M	22.6M	-22.47M	11.01M
OpEx % of Revenue	-	-	120.61%	8.83%	8.75%	13.24%	-	-	-114.74%	-
Selling, General & Admin	1.51M	3M	6.39M	5.19M	6.08M	5.71M	5.82M	5.96M	4.84M	2.94M
SG&A % of Revenue	-	-	63.88%	5.19%	6.08%	5.71%	-	-	24.74%	-
Research & Development	2.56M	4.18M	4.64M	5.27M	2.28M	7.49M	11.83M	16.32M	17.03M	7.62M
R&D % of Revenue	-	-	46.4%	5.27%	2.28%	7.49%	-	-	87%	-
Other Operating Expenses	0	0	1.03M	0	356K	293K	12K	321K	393K	450K
Operating Income+	-4.07M	-7.18M	-11.97M	-7.83M	-7.16M	-13.24M	-17.93M	-22.6M	-22.27M	-11.01M
Operating Margin %	-	-	-119.66%	-7.83%	-7.16%	-13.24%	-	-	-113.74%	-
Operating Income Growth %	0.21%	-0.77%	-0.67%	0.35%	0.09%	-0.85%	-0.35%	-0.26%	0.01%	0.51%
EBITDA+	-4.07M	-7.18M	-11.96M	-7.82M	-6.98M	-13M	-17.7M	-22.4M	-22.23M	-10.82M
EBITDA Margin %	-	-	-119.62%	-7.82%	-6.98%	-13%	-	-	-113.51%	-
EBITDA Growth %	0.22%	-0.77%	-0.67%	0.35%	0.11%	-0.86%	-0.36%	-0.27%	0.01%	0.51%
D&A (Non-Cash Add-back)	1K	2K	4K	7K	179K	235K	231K	201K	46K	186K
EBIT	-4.07M	-7.1M	-12.89M	-5.56M	-6.32M	-28.64M	-17.75M	-21.69M	-19.92M	-7.24M
Net Interest Income+	91K	132K	80K	84K	-30K	198K	108K	465K	-1.71M	-187K
Interest Income	94K	138K	106K	93K	151K	254K	320K	532K	474K	260K
Interest Expense	3K	6K	26K	9K	181K	56K	212K	67K	2.18M	447K
Other Income/Expense	-133K	-4.94M	-1.04M	2.26M	1.48M	-15.46M	108K	843K	2.29M	3.73M
Pretax Income+	-4.2M	-12.13M	-12.91M	-5.57M	-5.89M	-28.7M	-17.83M	-21.76M	-19.98M	-7.28M
Pretax Margin %	-	-	-129.13%	-5.57%	-5.89%	-28.7%	-	-	-102.03%	-
Income Tax+	0	6K	0	0	216K	0	0	0	0	0
Effective Tax Rate %	1%	1%	0.94%	0.93%	0.99%	0.98%	1.03%	1%	0%	0.99%
Net Income+	-4.2M	-12.13M	-12.18M	-5.2M	-5.85M	-28M	-18.38M	-21.67M	-19.88K	-7.24M
Net Margin %	-	-	-121.77%	-5.2%	-5.85%	-28%	-	-	-0.1%	-
Net Income Growth %	0.2%	-1.89%	-0%	0.57%	-0.13%	-3.79%	0.34%	-0.18%	1%	-363.19%
Net Income (Continuing)	-4.2M	-12.13M	-12.91M	-5.57M	-5.41M	-28.7M	-17.83M	-21.76M	-19.98M	-7.28M
Discontinued Operations	0	0	0	0	-485K	0	-642K	0	0	0
Minority Interest	0	0	1.28M	481K	438K	363K	279K	187K	90K	51K
EPS (Diluted)+	-8.75	-4.38	-2.65	-0.70	-0.59	-0.35	-0.21	-0.23	-0.16	-4.42
EPS Growth %	0.82%	0.5%	0.39%	0.74%	0.16%	0.41%	0.4%	-0.1%	0.3%	-26.63%
EPS (Basic)	-8.75	-4.38	-2.65	-0.70	-0.59	-0.35	-0.21	-0.23	-0.16	-4.42
Diluted Shares Outstanding	4.81K	28.78K	47.28K	71.03K	96.84K	860.53K	890K	924.08K	1.23M	2.59M
Basic Shares Outstanding	4.81K	28.78K	47.28K	71.03K	96.84K	860.53K	890K	924.08K	1.23M	2.59M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	10.8M	14.9M	7.98M	8.51M	8.3M	59.28M	48.47M	33.26M	15.79M	8.91M
Cash & Short-Term Investments	10.56M	14.66M	3.95M	5.16M	6.39M	57.8M	47.2M	32.11M	15.41M	8.52M
Cash Only	10.56M	6.76M	3.95M	5.16M	4.38M	11.25M	10.89M	15.03M	14.49M	7.4M
Short-Term Investments	0	7.9M	0	0	2.01M	46.56M	36.31M	17.08M	923K	1.12M
Accounts Receivable	0	0	0	743K	1.49M	500K	0	0	0	275K
Days Sales Outstanding	-	-	-	271.19	544.95	182.5	-	-	-	-
Inventory	-124K	-7.81M	0	778K	-1.49M	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	337K	824K	2.18M	197K	268K	146K	171K	109K
Total Non-Current Assets+	8K	16K	6.2M	6.21M	6.42M	24.52M	21.73M	21.37M	28.51M	28.13M
Property, Plant & Equipment	8K	16K	28K	37K	244K	968K	896K	682K	470K	288K
Fixed Asset Turnover	-	-	3.57x	27.03x	4.10x	1.03x	-	-	0.42x	-
Goodwill	0	0	0	0	0	20.46M	20.46M	20.66M	0	0
Intangible Assets	0	0	6.17M	6.17M	6.17M	20.48K	20.48K	20.68K	28.04M	27.84M
Long-Term Investments	0	0	0	0	0	0	187K	0	0	0
Other Non-Current Assets	0	0	0	0	0	3.07M	160K	0	0	0
Total Assets+	10.81M	14.91M	14.18M	14.72M	14.72M	83.8M	70.2M	54.62M	44.3M	37.04M
Asset Turnover	-	-	0.01x	0.07x	0.07x	0.01x	-	-	0.00x	-
Asset Growth %	5.15%	0.38%	-0.05%	0.04%	-0%	4.69%	-0.16%	-0.22%	-0.19%	-0.16%
Total Current Liabilities+	1.2M	1.27M	4.07M	3.31M	3.54M	3.1M	4.25M	7.06M	7.18M	3.99M
Accounts Payable	353K	515K	215K	705K	1.25M	1.2M	1.47M	2.13M	3.53M	1.46M
Days Payables Outstanding	-	-	-	-	1000K	1000K	1000K	1000K	6.58K	2.86K
Short-Term Debt	0	0	0	0	0	0	0	0	0	183K
Deferred Revenue (Current)	0	0	95K	0	961K	0	0	0	0	0
Other Current Liabilities	690K	682K	2.27M	721K	1.58M	584K	611K	698K	673K	966K
Current Ratio	9.02x	11.70x	1.96x	2.57x	2.34x	19.14x	11.41x	4.71x	2.20x	2.23x
Quick Ratio	9.12x	17.84x	1.96x	2.33x	2.76x	19.14x	11.41x	4.71x	2.20x	2.23x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	185K	256K	1.52M	405K	313K	953K	842K	466K	2.82M	140K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	28K	688K	550K	321K	163K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	185K	256K	1.52M	405K	285K	265K	292K	145K	2.66M	140K
Total Liabilities	1.38M	1.53M	5.59M	3.72M	3.86M	4.05M	5.09M	7.52M	10.01M	4.13M
Total Debt+	0	0	0	0	223K	895K	749K	515K	351K	183K
Net Debt	-10.56M	-6.76M	-3.95M	-5.16M	-4.16M	-10.35M	-10.14M	-14.52M	-14.14M	-7.22M
Debt / Equity	-	-	-	-	0.02x	0.01x	0.01x	0.01x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-1356.33x	-1197.17x	-460.23x	-869.56x	-39.54x	-236.41x	-84.59x	-337.36x	-10.21x	-24.62x
Total Equity+	9.43M	13.38M	8.59M	11M	10.86M	79.75M	65.11M	47.1M	34.3M	32.91M
Equity Growth %	11.2%	0.42%	-0.36%	0.28%	-0.01%	6.34%	-0.18%	-0.28%	-0.27%	-0.04%
Book Value per Share	1959.48	465.11	181.73	154.93	112.16	92.68	73.15	50.97	27.86	12.73
Total Shareholders' Equity	9.43M	13.38M	7.31M	10.52M	10.42M	79.39M	64.83M	46.91M	34.21M	32.86M
Common Stock	0	0	0	0	0	0	0	0	0	0
Retained Earnings	-14.05M	-26.2M	-38.57M	-43.67M	-49.52M	-77.52M	-95.91M	-117.58M	-137.45M	-144.69M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	1.3M	1.34M	2.49M	1.62M	3.08M	8.02M	8.76M	10.06M	-79K	-98K
Minority Interest	0	0	1.28M	481K	438K	363K	279K	187K	90K	51K

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.31M	-6.26M	-8.63M	-8.48M	-5.58M	-12.09M	-15.07M	-16.73M	-19.93M	-14.37M
Operating CF Margin %	-	-	-86.27%	-8.48%	-5.58%	-12.09%	-	-	-101.76%	-
Operating CF Growth %	0.27%	-0.89%	-0.38%	0.02%	0.34%	-1.17%	-0.25%	-0.11%	-0.19%	0.28%
Net Income	-4.2M	-12.13M	-13.01M	-5.57M	-5.89M	-28.07M	-17.83M	-21.76M	-19.88M	-7.28M
Depreciation & Amortization	1K	2K	4K	7K	179K	235K	231K	201K	197K	186K
Stock-Based Compensation	59K	400K	2.31M	773K	1.27M	2.65M	2.08M	2.41M	1.88M	582K
Deferred Taxes	0	0	0	-894K	0	0	0	0	0	0
Other Non-Cash Items	550K	5.19M	1.95M	-2.26M	-1.48M	15.46M	-108K	-843K	-2.39M	-3.52M
Working Capital Changes	284K	269K	122K	-540K	340K	-2.36M	550K	3.25M	274K	-4.33M
Change in Receivables	197K	0	0	-1.11M	1.55K	501K	-316K	313K	0	0
Change in Inventory	54K	0	0	0	-1.55K	-511K	573K	2.13M	0	0
Change in Payables	-152K	-138K	-491K	393K	503K	-2.33M	266K	799K	1.33M	-2.08M
Cash from Investing+	-9K	-7.91M	2.77M	2.04M	-449K	-49.59M	13.41M	19.91M	13.88M	509K
Capital Expenditures	-9K	-10K	-13K	-16K	-11K	-156K	-115K	-228K	-3K	0
CapEx % of Revenue	-	-	0.13%	0.02%	0.01%	0.16%	-	-	0.02%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-7.9M	4.52M	2.06M	151K	69K	359K	324K	755K	320K
Cash from Financing+	12.63M	10.42M	3M	7.79M	5.23M	68.49M	1.51M	1.11M	5.45M	6.77M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-341K	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-1.97M	4M	576K	3.1M	2.81M	40.74M	1.1M	-219K	4.05M	1.15M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.32M	-6.27M	-8.64M	-8.5M	-5.59M	-12.25M	-15.19M	-16.96M	-19.93M	-14.37M
FCF Margin %	-	-	-86.4%	-8.5%	-5.59%	-12.25%	-	-	-101.78%	-
FCF Growth %	0.27%	-0.89%	-0.38%	0.02%	0.34%	-1.19%	-0.24%	-0.12%	-0.17%	0.28%
FCF per Share	-689.32	-217.94	-182.73	-119.62	-57.75	-14.23	-17.06	-18.36	-16.19	-5.56
FCF Conversion (FCF/Net Income)	0.79x	0.52x	0.71x	1.63x	0.95x	0.43x	0.82x	0.77x	1002.26x	1.98x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-82.38%	-106.29%	-110.81%	-53.07%	-53.51%	-61.8%	-25.38%	-38.62%	-0.05%	-21.55%
Return on Invested Capital (ROIC)	-	-195.97%	-159.22%	-111.94%	-85.6%	-26.1%	-21.63%	-38.73%	-63.34%	-36%
Gross Margin	-	-	100%	100%	99.99%	99.99%	-	-	-0.1%	-
Net Margin	-	-	-12177%	-520%	-585%	-2799.9%	-	-	-10.15%	-
Debt / Equity	-	-	-	-	0.02x	0.01x	0.01x	0.01x	0.01x	0.01x
Interest Coverage	-1356.33x	-1197.17x	-460.23x	-869.56x	-39.54x	-236.41x	-84.59x	-337.36x	-10.21x	-24.62x
FCF Conversion	0.79x	0.52x	0.71x	1.63x	0.95x	0.43x	0.82x	0.77x	1002.26x	1.98x
Revenue Growth	-	-	-	900%	0%	0%	-100%	-	-	-100%

Frequently Asked Questions

Growth & Financials

Purple Biotech Ltd. (PPBT) saw revenue decline by 100.0% over the past year.

Purple Biotech Ltd. (PPBT) reported a net loss of $3.3M for fiscal year 2024.

Dividend & Returns

Purple Biotech Ltd. (PPBT) has a return on equity (ROE) of -21.5%. Negative ROE indicates the company is unprofitable.

Purple Biotech Ltd. (PPBT) had negative free cash flow of $5.5M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Purple Biotech Ltd. (PPBT) 10-Year Financial Performance & Capital Metrics

PPBT • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $0 -100.0%
EBITDA -$11M +51.3%
Net Income -$7M -36318.5%
EPS (Diluted) -4.42 -2662.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -21.55% -44049.8%
ROIC -36% +43.2%
Debt/Equity 0.01 -45.7%
Interest Coverage -24.62 -141.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓High quality earnings: Operating CF exceeds net income
✓Trading at only 0.1x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 9 (bottom 9%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM72.06%

EPS CAGR

10Y-

5Y-

3Y-

TTM-36734.22%

ROCE

10Y Avg-55.4%

5Y Avg-35.41%

3Y Avg-41.26%

Latest-31.37%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	100K	1M	1M	1M	0	0	195.8K	0
Revenue Growth %	-	-	-	9%	0%	0%	-1%	-	-	-1%
Cost of Goods Sold+	0	0	0	0	80	58	55	120	196K	186K
COGS % of Revenue	-	-	-	-	0%	0%	-	-	1%	-
Gross Profit+	0	0	100K	1M	999.92K	999.94K	-55	-120	-196	-186K
Gross Margin %	-	-	1%	1%	1%	1%	-	-	-0%	-
Gross Profit Growth %	-	-	-	9%	-0%	0%	-1%	-1.18%	-0.63%	-947.98%
Operating Expenses+	4.07M	7.18M	12.06M	8.83M	8.75M	13.24M	17.93M	22.6M	-22.47M	11.01M
OpEx % of Revenue	-	-	120.61%	8.83%	8.75%	13.24%	-	-	-114.74%	-
Selling, General & Admin	1.51M	3M	6.39M	5.19M	6.08M	5.71M	5.82M	5.96M	4.84M	2.94M
SG&A % of Revenue	-	-	63.88%	5.19%	6.08%	5.71%	-	-	24.74%	-
Research & Development	2.56M	4.18M	4.64M	5.27M	2.28M	7.49M	11.83M	16.32M	17.03M	7.62M
R&D % of Revenue	-	-	46.4%	5.27%	2.28%	7.49%	-	-	87%	-
Other Operating Expenses	0	0	1.03M	0	356K	293K	12K	321K	393K	450K
Operating Income+	-4.07M	-7.18M	-11.97M	-7.83M	-7.16M	-13.24M	-17.93M	-22.6M	-22.27M	-11.01M
Operating Margin %	-	-	-119.66%	-7.83%	-7.16%	-13.24%	-	-	-113.74%	-
Operating Income Growth %	0.21%	-0.77%	-0.67%	0.35%	0.09%	-0.85%	-0.35%	-0.26%	0.01%	0.51%
EBITDA+	-4.07M	-7.18M	-11.96M	-7.82M	-6.98M	-13M	-17.7M	-22.4M	-22.23M	-10.82M
EBITDA Margin %	-	-	-119.62%	-7.82%	-6.98%	-13%	-	-	-113.51%	-
EBITDA Growth %	0.22%	-0.77%	-0.67%	0.35%	0.11%	-0.86%	-0.36%	-0.27%	0.01%	0.51%
D&A (Non-Cash Add-back)	1K	2K	4K	7K	179K	235K	231K	201K	46K	186K
EBIT	-4.07M	-7.1M	-12.89M	-5.56M	-6.32M	-28.64M	-17.75M	-21.69M	-19.92M	-7.24M
Net Interest Income+	91K	132K	80K	84K	-30K	198K	108K	465K	-1.71M	-187K
Interest Income	94K	138K	106K	93K	151K	254K	320K	532K	474K	260K
Interest Expense	3K	6K	26K	9K	181K	56K	212K	67K	2.18M	447K
Other Income/Expense	-133K	-4.94M	-1.04M	2.26M	1.48M	-15.46M	108K	843K	2.29M	3.73M
Pretax Income+	-4.2M	-12.13M	-12.91M	-5.57M	-5.89M	-28.7M	-17.83M	-21.76M	-19.98M	-7.28M
Pretax Margin %	-	-	-129.13%	-5.57%	-5.89%	-28.7%	-	-	-102.03%	-
Income Tax+	0	6K	0	0	216K	0	0	0	0	0
Effective Tax Rate %	1%	1%	0.94%	0.93%	0.99%	0.98%	1.03%	1%	0%	0.99%
Net Income+	-4.2M	-12.13M	-12.18M	-5.2M	-5.85M	-28M	-18.38M	-21.67M	-19.88K	-7.24M
Net Margin %	-	-	-121.77%	-5.2%	-5.85%	-28%	-	-	-0.1%	-
Net Income Growth %	0.2%	-1.89%	-0%	0.57%	-0.13%	-3.79%	0.34%	-0.18%	1%	-363.19%
Net Income (Continuing)	-4.2M	-12.13M	-12.91M	-5.57M	-5.41M	-28.7M	-17.83M	-21.76M	-19.98M	-7.28M
Discontinued Operations	0	0	0	0	-485K	0	-642K	0	0	0
Minority Interest	0	0	1.28M	481K	438K	363K	279K	187K	90K	51K
EPS (Diluted)+	-8.75	-4.38	-2.65	-0.70	-0.59	-0.35	-0.21	-0.23	-0.16	-4.42
EPS Growth %	0.82%	0.5%	0.39%	0.74%	0.16%	0.41%	0.4%	-0.1%	0.3%	-26.63%
EPS (Basic)	-8.75	-4.38	-2.65	-0.70	-0.59	-0.35	-0.21	-0.23	-0.16	-4.42
Diluted Shares Outstanding	4.81K	28.78K	47.28K	71.03K	96.84K	860.53K	890K	924.08K	1.23M	2.59M
Basic Shares Outstanding	4.81K	28.78K	47.28K	71.03K	96.84K	860.53K	890K	924.08K	1.23M	2.59M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	10.8M	14.9M	7.98M	8.51M	8.3M	59.28M	48.47M	33.26M	15.79M	8.91M
Cash & Short-Term Investments	10.56M	14.66M	3.95M	5.16M	6.39M	57.8M	47.2M	32.11M	15.41M	8.52M
Cash Only	10.56M	6.76M	3.95M	5.16M	4.38M	11.25M	10.89M	15.03M	14.49M	7.4M
Short-Term Investments	0	7.9M	0	0	2.01M	46.56M	36.31M	17.08M	923K	1.12M
Accounts Receivable	0	0	0	743K	1.49M	500K	0	0	0	275K
Days Sales Outstanding	-	-	-	271.19	544.95	182.5	-	-	-	-
Inventory	-124K	-7.81M	0	778K	-1.49M	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	337K	824K	2.18M	197K	268K	146K	171K	109K
Total Non-Current Assets+	8K	16K	6.2M	6.21M	6.42M	24.52M	21.73M	21.37M	28.51M	28.13M
Property, Plant & Equipment	8K	16K	28K	37K	244K	968K	896K	682K	470K	288K
Fixed Asset Turnover	-	-	3.57x	27.03x	4.10x	1.03x	-	-	0.42x	-
Goodwill	0	0	0	0	0	20.46M	20.46M	20.66M	0	0
Intangible Assets	0	0	6.17M	6.17M	6.17M	20.48K	20.48K	20.68K	28.04M	27.84M
Long-Term Investments	0	0	0	0	0	0	187K	0	0	0
Other Non-Current Assets	0	0	0	0	0	3.07M	160K	0	0	0
Total Assets+	10.81M	14.91M	14.18M	14.72M	14.72M	83.8M	70.2M	54.62M	44.3M	37.04M
Asset Turnover	-	-	0.01x	0.07x	0.07x	0.01x	-	-	0.00x	-
Asset Growth %	5.15%	0.38%	-0.05%	0.04%	-0%	4.69%	-0.16%	-0.22%	-0.19%	-0.16%
Total Current Liabilities+	1.2M	1.27M	4.07M	3.31M	3.54M	3.1M	4.25M	7.06M	7.18M	3.99M
Accounts Payable	353K	515K	215K	705K	1.25M	1.2M	1.47M	2.13M	3.53M	1.46M
Days Payables Outstanding	-	-	-	-	1000K	1000K	1000K	1000K	6.58K	2.86K
Short-Term Debt	0	0	0	0	0	0	0	0	0	183K
Deferred Revenue (Current)	0	0	95K	0	961K	0	0	0	0	0
Other Current Liabilities	690K	682K	2.27M	721K	1.58M	584K	611K	698K	673K	966K
Current Ratio	9.02x	11.70x	1.96x	2.57x	2.34x	19.14x	11.41x	4.71x	2.20x	2.23x
Quick Ratio	9.12x	17.84x	1.96x	2.33x	2.76x	19.14x	11.41x	4.71x	2.20x	2.23x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	185K	256K	1.52M	405K	313K	953K	842K	466K	2.82M	140K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	28K	688K	550K	321K	163K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	185K	256K	1.52M	405K	285K	265K	292K	145K	2.66M	140K
Total Liabilities	1.38M	1.53M	5.59M	3.72M	3.86M	4.05M	5.09M	7.52M	10.01M	4.13M
Total Debt+	0	0	0	0	223K	895K	749K	515K	351K	183K
Net Debt	-10.56M	-6.76M	-3.95M	-5.16M	-4.16M	-10.35M	-10.14M	-14.52M	-14.14M	-7.22M
Debt / Equity	-	-	-	-	0.02x	0.01x	0.01x	0.01x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-1356.33x	-1197.17x	-460.23x	-869.56x	-39.54x	-236.41x	-84.59x	-337.36x	-10.21x	-24.62x
Total Equity+	9.43M	13.38M	8.59M	11M	10.86M	79.75M	65.11M	47.1M	34.3M	32.91M
Equity Growth %	11.2%	0.42%	-0.36%	0.28%	-0.01%	6.34%	-0.18%	-0.28%	-0.27%	-0.04%
Book Value per Share	1959.48	465.11	181.73	154.93	112.16	92.68	73.15	50.97	27.86	12.73
Total Shareholders' Equity	9.43M	13.38M	7.31M	10.52M	10.42M	79.39M	64.83M	46.91M	34.21M	32.86M
Common Stock	0	0	0	0	0	0	0	0	0	0
Retained Earnings	-14.05M	-26.2M	-38.57M	-43.67M	-49.52M	-77.52M	-95.91M	-117.58M	-137.45M	-144.69M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	1.3M	1.34M	2.49M	1.62M	3.08M	8.02M	8.76M	10.06M	-79K	-98K
Minority Interest	0	0	1.28M	481K	438K	363K	279K	187K	90K	51K

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.31M	-6.26M	-8.63M	-8.48M	-5.58M	-12.09M	-15.07M	-16.73M	-19.93M	-14.37M
Operating CF Margin %	-	-	-86.27%	-8.48%	-5.58%	-12.09%	-	-	-101.76%	-
Operating CF Growth %	0.27%	-0.89%	-0.38%	0.02%	0.34%	-1.17%	-0.25%	-0.11%	-0.19%	0.28%
Net Income	-4.2M	-12.13M	-13.01M	-5.57M	-5.89M	-28.07M	-17.83M	-21.76M	-19.88M	-7.28M
Depreciation & Amortization	1K	2K	4K	7K	179K	235K	231K	201K	197K	186K
Stock-Based Compensation	59K	400K	2.31M	773K	1.27M	2.65M	2.08M	2.41M	1.88M	582K
Deferred Taxes	0	0	0	-894K	0	0	0	0	0	0
Other Non-Cash Items	550K	5.19M	1.95M	-2.26M	-1.48M	15.46M	-108K	-843K	-2.39M	-3.52M
Working Capital Changes	284K	269K	122K	-540K	340K	-2.36M	550K	3.25M	274K	-4.33M
Change in Receivables	197K	0	0	-1.11M	1.55K	501K	-316K	313K	0	0
Change in Inventory	54K	0	0	0	-1.55K	-511K	573K	2.13M	0	0
Change in Payables	-152K	-138K	-491K	393K	503K	-2.33M	266K	799K	1.33M	-2.08M
Cash from Investing+	-9K	-7.91M	2.77M	2.04M	-449K	-49.59M	13.41M	19.91M	13.88M	509K
Capital Expenditures	-9K	-10K	-13K	-16K	-11K	-156K	-115K	-228K	-3K	0
CapEx % of Revenue	-	-	0.13%	0.02%	0.01%	0.16%	-	-	0.02%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-7.9M	4.52M	2.06M	151K	69K	359K	324K	755K	320K
Cash from Financing+	12.63M	10.42M	3M	7.79M	5.23M	68.49M	1.51M	1.11M	5.45M	6.77M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-341K	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-1.97M	4M	576K	3.1M	2.81M	40.74M	1.1M	-219K	4.05M	1.15M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.32M	-6.27M	-8.64M	-8.5M	-5.59M	-12.25M	-15.19M	-16.96M	-19.93M	-14.37M
FCF Margin %	-	-	-86.4%	-8.5%	-5.59%	-12.25%	-	-	-101.78%	-
FCF Growth %	0.27%	-0.89%	-0.38%	0.02%	0.34%	-1.19%	-0.24%	-0.12%	-0.17%	0.28%
FCF per Share	-689.32	-217.94	-182.73	-119.62	-57.75	-14.23	-17.06	-18.36	-16.19	-5.56
FCF Conversion (FCF/Net Income)	0.79x	0.52x	0.71x	1.63x	0.95x	0.43x	0.82x	0.77x	1002.26x	1.98x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-82.38%	-106.29%	-110.81%	-53.07%	-53.51%	-61.8%	-25.38%	-38.62%	-0.05%	-21.55%
Return on Invested Capital (ROIC)	-	-195.97%	-159.22%	-111.94%	-85.6%	-26.1%	-21.63%	-38.73%	-63.34%	-36%
Gross Margin	-	-	100%	100%	99.99%	99.99%	-	-	-0.1%	-
Net Margin	-	-	-12177%	-520%	-585%	-2799.9%	-	-	-10.15%	-
Debt / Equity	-	-	-	-	0.02x	0.01x	0.01x	0.01x	0.01x	0.01x
Interest Coverage	-1356.33x	-1197.17x	-460.23x	-869.56x	-39.54x	-236.41x	-84.59x	-337.36x	-10.21x	-24.62x
FCF Conversion	0.79x	0.52x	0.71x	1.63x	0.95x	0.43x	0.82x	0.77x	1002.26x	1.98x
Revenue Growth	-	-	-	900%	0%	0%	-100%	-	-	-100%

Frequently Asked Questions

Growth & Financials

Purple Biotech Ltd. (PPBT) saw revenue decline by 100.0% over the past year.

Purple Biotech Ltd. (PPBT) reported a net loss of $3.3M for fiscal year 2024.

Dividend & Returns

Purple Biotech Ltd. (PPBT) has a return on equity (ROE) of -21.5%. Negative ROE indicates the company is unprofitable.

Purple Biotech Ltd. (PPBT) had negative free cash flow of $5.5M in fiscal year 2024, likely due to heavy capital investments.